Clinical trials: Placebo Response
Arthritis, Rheumatoid
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors
This study (contRAst 3 [202018: NCT04134728]) is a Phase 3, randomized, multicenter, double-blind study to assess the safety and efficacy of GSK3196165 in combination with conventional (cs) DMARD[s]) or the treatment of adult…
- Trial name
- contRAst 3 (NCT04134728)
- Testing
- GSK3196165 (Otilimab), Sarilumab, csDMARDs
- Where
- 131 sites in United States, Argentina and 13 more
- Volunteers
- 550 people
- Sponsor
- GlaxoSmithKline
Cytokine Storm (Covid-19)
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
This was a randomized, double-blind, placebo-controlled, 29-day, multicenter study to assess the efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy, compared with placebo + SoC therapy, in patients aged ≥12 years…
- Trial name
- RUXCOVID (NCT04362137)
- Testing
- Ruxolitinib
- Where
- 61 sites in United States, Argentina and 10 more
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Sleep Disorders
Characteristics of Sleep Patterns in Young Adults With and Without Insomnia
This study will compare the symptoms, experiences, and laboratory sleep characteristics of young adults with and without insomnia.
- Trial name
- NCT00177216
- Testing
- Zolpidem, Escitalopram
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Hypersensitivity
The Duration of the Suppressive Effects of Desloratadine on Allergen Prick Tests After Discontinuation (P04441)
This is a randomized, double-blind, double-dummy, placebo-controlled, parallel-group, single center study in subjects with positive histamine skin prick test and a positive RadioAllergoSorbent Test (RAST) (class > 2) to one of…
- Trial name
- NCT00359138
- Testing
- desloratadine, levocetirizine
- Volunteers
- 36 people
- Sponsor
- Organon and Co
Chronic Insomnia, Adults
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia
This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, parallel-group, Bayesian adaptive, dose response study in subjects with chronic insomnia.
- Conditions
- Chronic Insomnia, Adults, Elderly
- Trial name
- NCT01995838
- Testing
- E2006
- Where
- 29 sites in United States
- Volunteers
- 291 people
- Sponsor
- Eisai Inc.
Spondylitis, Ankylosing
A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy
This randomized, double-blind, placebo-controlled study evaluated the safety and efficacy of tocilizumab (RoActemra/Actemra) in patients with ankylosing spondylitis (AS) who had an inadequate response to previous tumor necrosis…
- Trial name
- NCT01209689
- Testing
- Tocilizumab
- Where
- 140 sites in United States, Australia and 17 more
- Volunteers
- 113 people
- Sponsor
- Hoffmann-La Roche
Eosinophilic Duodenitis, Eosinophilic Gastroenteritis
A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis
This is a Phase 3, multi-center, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of lirentelimab (AK002) given monthly for 6 doses in adult patients with active eosinophilic duodenitis.
- Trial name
- EoDyssey (NCT04856891)
- Testing
- AK002
- Where
- 39 sites in United States
- Volunteers
- 94 people
- Sponsor
- Allakos Inc.
Lung Cancer
Metformin in Non Small Cell Lung Cancer (NSCLC)
The goal of this clinical research study is to learn if giving metformin in combination with radiation therapy is more effective than radiation therapy alone.
- Trial name
- NCT02285855
- Testing
- Metformin, Stereotactic body Radiotherapy (SBRT)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Myelodysplastic Syndromes
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
The purpose of this study was to compare 2 doses (10 mg and 5 mg) of lenalidomide to that of placebo in subjects with red blood cell (RBC) transfusion-dependent low- or intermediate-1-risk IPSS MDS associated with a deletion…
- Trial name
- NCT00179621
- Testing
- Lenalidomide 5 mg, Lenalidomide 10 mg
- Where
- 38 sites in Belgium, France and 7 more
- Volunteers
- 205 people
- Sponsor
- Celgene Corporation
Type 2 Diabetes Mellitus
Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338)(COMPLETED)
The purpose of this study is to evaluate the effect of SCH 497079 on metabolic parameters and to determine the influence of race/ethnic origin on therapeutic response.
- Trial name
- NCT00673465
- Testing
- SCH 497079, Metformin
- Volunteers
- 17 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)
The objective of this trial is to investigate the efficacy (American College of Rheumatology 20% : ACR20) superiority of two dose regiments of CDP870 versus placebo in combination with MTX in active RA patients who have an…
- Trial name
- NCT00791999
- Testing
- CDP870 400mg, CDP870 200mg, CDP870 100mg
- Where
- 8 sites in Japan
- Volunteers
- 316 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Gastroparesis
Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis
GSK962040 is a novel small molecule motilin agonist. The Phase I studies (MOT107043 and MOT109681) demonstrated that single doses of GSK962040 up to 150 mg and repeat dosing of up to 125 mg/day for 14 days were well tolerated…
- Trial name
- NCT01262898
- Testing
- GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet)
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 79 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.
The purpose of this study is to assess the safety and effect of TC-5214 as a single therapy in patients with major depressive disorder who exhibit inadequate response to antidepressants.
- Trial name
- NCT01288079
- Testing
- TC-5214, Duloxetine
- Where
- 63 sites in United States, Estonia and 3 more
- Volunteers
- 145 people
- Sponsor
- AstraZeneca
Major Depressive Disorder
Closed-loop Optimized rTMS for Depression
Targeted and individualized treatments for mental health disorders are critically needed. Repetitive transcranial magnetic stimulation (rTMS) represents the front-line of new and innovative approaches to normalizing dysfunctional…
- Trial name
- NCT04142320
- Testing
- Neuronavigated rTMS
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Stanford University
Chordoma
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
This is a phase 2 clinical trial to determine whether the yeast-brachyury vaccine GI-6301 improves the effectiveness of radiation for patients with localized chordoma.
- Trial name
- NCT02383498
- Testing
- GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NantCell, Inc.
Type 2 Diabetes Mellitus and Microalbuminuria
A Phase 2 Dose-finding Study of TAK-272 in Participants With Type 2 Diabetes Mellitus and Microalbuminuria
The purpose of this study is to test the efficacy and safety on daily oral doses of TAK-272 5 mg, 20 mg, 40 mg and 80 mg in patients with type 2 diabetes mellitus and microalbuminuria by randomized, double-blind…
- Trial name
- NCT02332824
- Testing
- TAK-272, Candesartan cilexetil
- Where
- 68 sites in Japan
- Volunteers
- 415 people
- Sponsor
- Takeda
Gastroparesis
Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis
This is a randomized, double-blind, placebo-controlled study that will compare the effect of 2 different dosage regimens of PCS12852 on gastric emptying time to placebo in both idiopathic gastroparesis (IG) and diabetic…
- Trial name
- MOMENTUM (NCT05270460)
- Testing
- PCS12852
- Where
- 9 sites in United States
- Volunteers
- 25 people
- Sponsor
- Processa Pharmaceuticals
Major Depressive Disorder
A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD)
This study will evaluate the efficacy of ALKS 5461 when administered daily for 4 weeks to adults with Major Depressive Disorder (MDD) and inadequate response to antidepressant therapy.
- Trial name
- NCT01500200
- Testing
- ALKS 5461
- Where
- 27 sites in United States
- Volunteers
- 142 people
- Sponsor
- Alkermes, Inc.
Asthma
A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise
This study is intended to determine the dose response and duration of action of GSK2190915 in mild asthmatic adult subjects who experience exercise-induced bronchoconstriction.
- Trial name
- NCT00812929
- Testing
- GSK2190915
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- GlaxoSmithKline
Post Surgical Pain
Dose Response Study of Dexamethasone in Combination With Bupivacaine 0.25%
When used in conjunction with a local anesthetic, dexamethasone may prolong both the sensory and motor effects of high supraclavicular brachial plexus nerve block (SBP) in arthroscopic shoulder surgery.
- Trial name
- Dex Dose (NCT01690663)
- Testing
- Bupivacaine 0.25%, Dexamethasone, normal saline
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- University of Pennsylvania